Novartis planning to invest EUR 6m in clinical trials over the next 5 years in Portugal
|
03 APR 2023
|
Intel ID : 362617
|
||||
| Intel ID | 362617 | |
| Value | EUR 6,00m | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Novartis
(31 Dec 2016) |
Exchange Rate: 
|
|
| Date |
|
|
| Country |  |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Primary Subsector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.